Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD84 is a survival receptor for CLL cells.
Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-Halevy I, Kay S, Aloshin A, Sagi I, Goldenberg DM, Leng L, Bucala R, Herishanu Y, Haran M, Shachar I. Binsky-Ehrenreich I, et al. Among authors: haran m. Oncogene. 2014 Feb 20;33(8):1006-16. doi: 10.1038/onc.2013.31. Epub 2013 Feb 25. Oncogene. 2014. PMID: 23435417 Free PMC article.
IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.
Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, Leng L, Goldenberg DM, Shvidel L, Berrebi A, Bucala R, Shachar I. Binsky I, et al. Among authors: haran m. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13408-13. doi: 10.1073/pnas.0701553104. Epub 2007 Aug 8. Proc Natl Acad Sci U S A. 2007. PMID: 17686984 Free PMC article.
CD84 mediates CLL-microenvironment interactions.
Marom A, Barak AF, Kramer MP, Lewinsky H, Binsky-Ehrenreich I, Cohen S, Tsitsou-Kampeli A, Kalchenko V, Kuznetsov Y, Mirkin V, Dezorella N, Shapiro M, Schwartzberg PL, Cohen Y, Shvidel L, Haran M, Becker-Herman S, Herishanu Y, Shachar I. Marom A, et al. Among authors: haran m. Oncogene. 2017 Feb 2;36(5):628-638. doi: 10.1038/onc.2016.238. Epub 2016 Jul 25. Oncogene. 2017. PMID: 27452524
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Haran M, Mirkin V, Braester A, Harpaz N, Shevetz O, Shtreiter M, Greenberg S, Mordich O, Amram O, Binsky-Ehrenreich I, Marom A, Shachar I, Herishanu Y, Ruchlemer R, Berrebi A, Valinsky L, Shtalrid M, Shvidel L. Haran M, et al. Br J Haematol. 2018 Jul;182(1):125-128. doi: 10.1111/bjh.14726. Epub 2017 May 3. Br J Haematol. 2018. PMID: 28466956 Free article. Clinical Trial. No abstract available.
123 results